Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment

To determine the efficacy and toxicity of Pemetrexed plus Oxaliplatin in patients suffering from stage IIIb or IV lung adenocarcinoma and being treated with Erlotinib as second-line treatment, a total of 45 patients were randomly divided into two groups. One group was treated with 500 mg/m(2) Pemetr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Sheng-Bin, Hu, Rong-Hang, Qi, Jie-Lin, Tang, Xiao-Yong, Tian, Jing, Li, Rui, Chang, Chun-Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667368/
https://www.ncbi.nlm.nih.gov/pubmed/23576138
http://dx.doi.org/10.1007/s12032-013-0550-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667368/
https://www.ncbi.nlm.nih.gov/pubmed/23576138
http://dx.doi.org/10.1007/s12032-013-0550-7

Ejemplares similares